In approximately one-third of primary hyperoxaluria type 1 patients, disease is associated with a unique protein sorting defect in which hepatic L-alanine:glyoxylate aminotransferase (AGT; EC 2.6.1.44), which is normally peroxisomal, is mistargeted to mitochondria. In all such patients analyzed to date, the gene encoding the aberrantly targeted AGT carries three point mutations, each of which specifies an amino acid substitution. In this paper we show that one of these substitutions, a proline-to-leucine at residue 11, is necessary and sufficient for the generation of a mitochondrial targeting sequence in the AGT protein. AGT with this substitution appears to interact specifically with the mitochondrial protein import machinery, via a discrete N-terminal domain of the AGT protein. The N-terminal 19 amino acids of AGT with this substitution are sufficient to direct mouse cytosolic dihydrofolate reductase to mitochondria, and a synthetic peptide corresponding to this same 19-amino acid region reversibly inhibits mitochondrial protein import, not only of AGT but also of ornithine transcarbamoylase, a genuine cytoplasmically synthesized mitochondrial protein. We have extended these studies to analyze a region of normal human AGT cDNA directly upstream of the coding region. This sequence appears to correspond to an ancestral mitochondrial targeting sequence deleted from the human coding region by point mutation at the initiation codon. We show that reestablishment ofthis initiation codon produces an active mitochondrial targeting sequence that is different to that found in the hyperoxaluria patients. These results are discussed with reference to the AGT targeting defect in primary hyperoxaluria and also in relation to the highly unusual species specificity of subcellular distribution of AGT among mammals.Primary hyperoxaluria type 1 (PHi) is a lethal autosomal recessive disease caused by a deficiency of the liver-specific peroxisomal enzyme L-alanine:glyoxylate aminotransferase (AGT; EC 2.6.1.44) (1). Whereas the majority ofPHi patients have a complete deficiency of AGT catalytic activity (2) and AGT immunoreactive protein (3), approximately one-third possess significant levels of residual AGT activity and protein. In all of these latter patients so far examined it appears that the disease is due, at least in part, to a unique protein sorting defect in which AGT is erroneously targeted to the mitochondrion instead of its normal intracellular location, the peroxisome (4). In an attempt to explain the molecular basis of this protein mistargeting phenomenon, we recently cloned and sequenced AGT cDNA from the liver of a PH1 patient with mitochondrial AGT (mAGT) and compared this with the sequence of normal human liver AGT cDNA (5, 6). This identified the presence of three point mutations, each specifying an amino acid substitution, which were subsequently shown to be common to all PH1 patients with mAGT analyzed to date (6). One of these substitutions, a proline-toleucine at residue 11 of the AGT protein (Pro-11-...